Michael Ryskin
Stock Analyst at B of A Securities
(1.37)
# 3,340
Out of 4,847 analysts
35
Total ratings
47.83%
Success rate
-5.04%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $48 → $68 | $61.96 | +9.75% | 5 | May 20, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.23 | +258.74% | 3 | Mar 3, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $475 → $535 | $525.83 | +1.74% | 2 | Feb 4, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $179.16 | +14.98% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $45.79 | -12.64% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.43 | +74.95% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $11.46 | +109.42% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.15 | +82.51% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $170.30 | +5.70% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $4.39 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $22.90 | +127.07% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.78 | +259.71% | 2 | Nov 10, 2021 | |
Tempus AI
May 20, 2025
Maintains: Neutral
Price Target: $48 → $68
Current: $61.96
Upside: +9.75%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.23
Upside: +258.74%
IDEXX Laboratories
Feb 4, 2025
Maintains: Neutral
Price Target: $475 → $535
Current: $525.83
Upside: +1.74%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $179.16
Upside: +14.98%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $45.79
Upside: -12.64%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.43
Upside: +74.95%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $11.46
Upside: +109.42%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.15
Upside: +82.51%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $170.30
Upside: +5.70%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.39
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $22.90
Upside: +127.07%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.78
Upside: +259.71%